Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 4 de 4
Filter
1.
Acta Clin Belg ; 77(6): 897-905, 2022 Dec.
Article in English | MEDLINE | ID: mdl-34789066

ABSTRACT

INTRODUCTION: Abiraterone acetate + prednisone (AAP) and docetaxel have proven their efficacy in the treatment of patients with newly diagnosed metastatic hormone-sensitive prostate cancer (mHSPC) in clinical trials. However, real-world data are scarce. The goal of this study is to evaluate real-world data on the efficacy and safety of these therapies in mHSPC patients. PATIENTS AND METHODS: Records of 93 patients from 21 different centres were retrospectively reviewed. Primary and secondary endpoints were radiographic and PSA progression-free survival (RPFS - PSA-PFS) and cancer specific and overall survival (CSS - OS), respectively. Adverse events (AEs) were evaluated according to the Common Terminology Criteria for Adverse Events version 5.0. Differences in oncological outcome and AEs were evaluated between three treatment groups: ADT only (N=26) - ADT + AAP (N=48) - ADT + docetaxel (N=19). Survival analysis was performed using Kaplan-Meier statistics. RESULTS: Median RPFS was 13 months (95% confidence interval [CI]: 9-17) for ADT only, 21 months (95% CI: 19-23) for ADT + AAP and 12 months (95% CI: 11-14) for ADT + docetaxel (p = 0.004). The 1-year PSA-PFS, CSS and OS were 73.5%, 90.7% and 88.7%, respectively, with no significant differences between the three groups. Adverse events of grade 3 or higher were not observed more frequently. CONCLUSION: Retrospective real-world data show a significantly longer RPFS for mHSPC patients treated with ADT + AAP compared to ADT only or ADT + docetaxel at short-term follow-up. This can aid in counselling of mHSPC patients in daily clinical practice.


Subject(s)
Abiraterone Acetate , Prostatic Neoplasms , Male , Humans , Abiraterone Acetate/therapeutic use , Docetaxel/therapeutic use , Androgen Antagonists/therapeutic use , Retrospective Studies , Prednisone/therapeutic use , Prostate-Specific Antigen/therapeutic use , Belgium/epidemiology , Data Analysis , Prostatic Neoplasms/drug therapy , Prostatic Neoplasms/pathology , Antineoplastic Combined Chemotherapy Protocols/therapeutic use , Hormones/therapeutic use , Treatment Outcome
2.
Eur J Obstet Gynecol Reprod Biol ; 207: 89-93, 2016 Dec.
Article in English | MEDLINE | ID: mdl-27833061

ABSTRACT

OBJECTIVE: To investigate the long-term outcomes of unilateral mid-urethral sling transection to treat voiding dysfunction after synthetic mid-urethral sling placement for stress urinary incontinence. STUDY DESIGN: Twenty-three patients who underwent an unilateral sling transection were analyzed retrospectively. Patient records were analyzed for subjective outcome, and pre- and postoperative flow patterns were used as objective outcome parameters. RESULTS: At the first postoperative follow-up, 77.3% of the patients remained dry. After a mean follow-up of 42 months, 73.9% of patients were continent. The flow pattern after lateral sling transection was significantly better than pre-operatively, with higher maximum flow rate (24.2ml/s, p=0.001), higher mean flow rate (10.4ml/s, p=0.001), higher voided volume (308.5ml, p=0.002) and lower residual volume (28.7ml, p=0.003). At final postoperative follow-up, eight patients (34.8%) reported urgency and six patients (26.1%) were incontinent; four of these patients (17.4%) mainly had urge incontinence. CONCLUSIONS: Unilateral mid-urethral sling transection is a safe, effective technique to treat voiding symptoms with good preservation of continence. The technique repairs the obstructive flow effectively. Urgency and urge incontinence after mid-urethral sling placement are difficult to treat with transection alone.


Subject(s)
Dyspareunia/etiology , Postoperative Complications/etiology , Suburethral Slings/adverse effects , Urinary Incontinence, Stress/surgery , Urinary Incontinence, Urge/etiology , Urinary Retention/etiology , Urinary Tract Infections/etiology , Belgium/epidemiology , Cohort Studies , Dyspareunia/epidemiology , Dyspareunia/physiopathology , Dyspareunia/prevention & control , Electronic Health Records , Female , Follow-Up Studies , Humans , Middle Aged , Patient Satisfaction , Postoperative Complications/epidemiology , Postoperative Complications/physiopathology , Postoperative Complications/prevention & control , Recurrence , Retrospective Studies , Risk , Secondary Prevention , Urinary Incontinence, Stress/epidemiology , Urinary Incontinence, Stress/physiopathology , Urinary Incontinence, Stress/prevention & control , Urinary Incontinence, Urge/epidemiology , Urinary Incontinence, Urge/physiopathology , Urinary Incontinence, Urge/prevention & control , Urinary Retention/epidemiology , Urinary Retention/physiopathology , Urinary Retention/prevention & control , Urinary Tract Infections/epidemiology , Urinary Tract Infections/physiopathology , Urinary Tract Infections/prevention & control , Urodynamics
4.
Fetal Diagn Ther ; 15(3): 127-31, 2000.
Article in English | MEDLINE | ID: mdl-10781994

ABSTRACT

OBJECTIVES: To evaluate the feasibility and accuracy of continuous fetal monitoring with a multiparameter intravascular sensor (MPIS) in animal models mimicking the fetal metabolic status. METHODS: First, the accuracy of the MPIS in hypoxic conditions was tested in adult rabbits (n = 6). The carotid artery (n = 4) or vein (n = 2) was catheterized with a 20-gauge cannula, housing a 500-microm Neotrend((R)) fiberoptic sensor for pCO(2), pO(2), pH and temperature. Fiberoptic readings were compared with arterial blood-gas (ABG) analyses. Secondly, the feasibility of continuous fetal fiberoptic sensing was tested during experimental fetoscopic surgery in lambs (n = 4). An identical sensor was introduced in a chorionic artery and readings were compared to ABG analyses of fetal blood samples. RESULTS: The overall bias and precision in the first experiment (147 measurement pairs) were -4.2 and 10.9 mm Hg for pO(2), +1.6 and 8.2 mm Hg for pCO(2) and -0.015 and 0.031 for pH, respectively. In the sheep experiments, continuous readings for all parameters were only available during 50% of the operation time, mainly due to disturbances induced by movement, contact with vessel wall and interference by endoscopic light. 20 sample pairs were obtained resulting in an overall bias and precision of -3.9 and 4.3 mm Hg for pO(2), -0.74 and 3.68 mm Hg for pCO(2) and -0.0032 and 0. 02 for pH. CONCLUSIONS: Fiberoptic microsensors are potentially useful for monitoring acid-base status in the low pO(2) range present in fetal life.


Subject(s)
Carbon Dioxide/blood , Fetal Monitoring/methods , Fiber Optic Technology , Oxygen/blood , Animals , Fetoscopy , Hydrogen-Ion Concentration , Hypoxia/blood , Rabbits , Sensitivity and Specificity , Sheep/embryology
SELECTION OF CITATIONS
SEARCH DETAIL